Results 1 to 10 of about 17,219,459 (310)

Therapeutic potential of targeting LAG-3 in cancer [PDF]

Journal for ImmunoTherapy of Cancer
Immune checkpoint inhibitors targeting negative regulatory checkpoints including programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 have produced significant improvements in progression-free survival (PFS) and overall survival in ...
Diwakar Davar, Ana Carrizosa Anderson, Ivan Diaz-Padilla   +2 more
doaj   +4 more sources

Clinical landscape of LAG-3-targeted therapy

Immuno-Oncology and Technology, 2022
Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions.
L. Chocarro, E. Blanco, H. Arasanz, L. Fernández-Rubio, A. Bocanegra, M. Echaide, M. Garnica, P. Ramos, G. Fernández-Hinojal, R. Vera, G. Kochan, D. Escors   +11 more
doaj   +7 more sources

LAG-3 : recent developments in combinational therapies in cancer. [PDF]

Cancer Sci
The study of anticancer immune responses and in particular the action of immune checkpoint inhibitors that overcome T cell inhibition has revolutionized metastatic patients' care.
Chavanton A, Mialhe F, Abrey J, Baeza Garcia A, Garrido C.   +4 more
europepmc   +4 more sources

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

OncoImmunology, 2023
Lymphocyte-activation gene-3 (LAG-3), an immune checkpoint receptor, negatively regulates T-cell function and facilitates immune escape of tumors. Dual inhibition of LAG-3 and programmed cell death receptor-1 (PD-1) significantly improved progression ...
Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer   +9 more
doaj   +4 more sources

Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review [PDF]

Frontiers in Oncology
Lymphocyte activation gene 3 (LAG-3), also known as CD223, is an emerging immune checkpoint that follows PD-1 and CTLA-4. Several LAG-3 targeting inhibitors in clinical trials and the combination of relatlimab (anti-LAG-3) and nivolumab (anti-PD-1) have ...
Yingzhe Luo, Xuebin Cai, Biao Yang, Facheng Lu, Cheng Yi, Guoyu Wu   +5 more
doaj   +3 more sources

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

Journal of Hematology & Oncology, 2023
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies.
Letong Cai, Yuchen Li, Jiaxiong Tan, Ling Xu, Yangqiu Li   +4 more
doaj   +2 more sources

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

OncoImmunology, 2021
Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority of patients do not respond to it.
Haiping Jiang, Haiqing Ni, Pan Zhang, Xiaoli Guo, Min Wu, Haoran Shen, Jie Wang, Weiwei Wu, Zhihai Wu, Jiazheng Ding, Rong Tang, Shuaixiang Zhou, Bingliang Chen, Michael Yu, Hua Jing, Junjian Liu   +15 more
doaj   +2 more sources

The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application

Frontiers in Immunology, 2022
LAG-3, a type of immune checkpoint receptor protein belonging to the immunoglobulin superfamily, is confirmed to be expressed on activated immune cells, mainly including activated T cells.
Jin-Ling Huo, Ya-Tao Wang, Wen-Jia Fu, Nan Lu, Zhang-Suo Liu   +4 more
doaj   +2 more sources

Combination immunotherapy targeting LAG-3, PD-1 and STING suppresses hepatocellular carcinoma as monitored by LAG-3 targeted PET imaging [PDF]

Biomarker Research
Background The low response rate of anti-PD-1 monoclonal antibodies (mAbs) in hepatocellular carcinoma (HCC) requires the development of combination immunotherapy strategies to improve their efficacy. This study aimed to use LAG-3-targeted PET imaging to
Zhen Quan, Yu Gao, Bo Sun, Yiwan Guo, Ziwei Jin, Na Hao, Dawei Jiang, Chuansheng Zheng, Xin Li, Quan Chen   +9 more
doaj   +2 more sources

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics

Cancer Medicine, 2023
Background Lymphocyte activation gene 3 (LAG‐3) or CD223 is a transmembrane protein that serves as an immune checkpoint which attenuates T‐cell activation.
Jacob J. Adashek, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Pradip De, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M. Conroy, Paul DePietro, Scott Lippman, Razelle Kurzrock   +11 more
doaj   +2 more sources